HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
HSCS
HeartSciences Inc.
There isn't enough reported data to score HSCS yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
HSCS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
HSCS's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
HSCS PE Valuation
HSCS has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
HSCS Forward outlook
There aren't enough analyst estimates for HSCS to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
HSCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.76 | +$5.52 |
| Q2 2026 | -$3.48 | +$5.86 |
| Q1 2024 | -$46.00 | +$84.03 |
| Q4 2023 | -$59.00 | +$92.30 |
| Q3 2023 | -$65.00 | +$95.53 |
| Q2 2023 | -$80.00 | +$67.67 |
| Q1 2023 | -$130.03 | -$20.69 |
HSCS has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over HSCS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over HSCS on profitability, with a higher operating margin.
HSCS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.1K | +11% |
| Q1 2024 | $14.7K | +654% |
| Q1 2023 | $2K | -29% |
| Q3 2022 | $3.2K | -57% |
| Q2 2022 | $4.1K | -72% |
HSCS's revenue is recovering but still below its 2021 peak: $2,100 last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -139957% | -41319 points |
| Q4 2025 | -85713% | N/A |
| Q3 2025 | -98638% | N/A |
| Q1 2024 | -10377% | +56767 points |
| Q4 2023 | -40255% | N/A |
| Q1 2023 | -67144% | -26987 points |
| Q3 2022 | -44691% | -35679 points |
| Q2 2022 | -47670% | -42410 points |
HSCS's operating margin was −139957% last quarter, down 99702 points from the same quarter a year ago, near the bottom of its range since 2021.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HSCS has the stronger cash trend. Its trailing FCF is down 11% versus its history, compared with HIMS at down 84%.
HSCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.3M | +$634.5K |
| Q2 2026 | -$1.7M | -$85.9K |
| Q1 2026 | -$1.5M | +$167K |
| Q3 2025 | -$2M | +$65.4K |
| Q2 2025 | -$1.6M | -$5.5K |
| Q1 2025 | -$1.6M | +$530.1K |
| Q3 2024 | -$2M | -$609.5K |
| Q2 2024 | -$1.6M | +$284.1K |
HSCS has burned cash in almost every quarter: −$6M over the past year, against −$7M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over HSCS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
HSCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +507K shares |
| 1 year | +272% | +2.7M shares |
| 3 years | +6399% | +3.6M shares |
HSCS has 4M diluted shares, up 272% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
HSCS Net Leverage
HSCS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
HSCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 26.7 | Neutral |
HSCS's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
HSCS PE vs Healthcare Sector
HSCS has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
HSCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.35 | 33% below |
| 20 week MA | $3.09 | 27% below |
| 50 week MA | $2.73 | 17% below |
| 100 week MA | $3.07 | 26% below |
| 200 week MA | $24.3 | 91% below |
HSCS is in a downtrend: it's below all five of its weekly moving averages, and 91% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
HSCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $208.0 | $89.0 | -57% |
| 2023 | $89.0 | $17.1 | -81% |
| 2024 | $17.1 | $3.81 | -78% |
| 2025 | $3.81 | $2.85 | -25% |
| 2026 YTD | $2.85 | $2.26 | -21% |
HSCS has the edge over HIMS on returns for 2026, with the stronger performance.